about
Development of autoimmune hair loss disease alopecia areata is associated with cardiac dysfunction in C3H/HeJ miceOxytocin and boneThe atherogenic Scarb1 null mouse model shows a high bone mass phenotypeOsteoimmunopathology in HIV/AIDS: A Translational Evidence-Based PerspectiveRole of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research.Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton.Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signalingFunctional melanocortin-2 receptors are expressed by mouse aorta-derived mesenchymal progenitor cells.Systemic and local ACTH produced during inflammatory states promotes osteochondrogenic mesenchymal cell differentiation contributing to the pathologic progression of calcified atherosclerosis.Functions of vasopressin and oxytocin in bone mass regulation.ACTH promotes chondrogenic nodule formation and induces transient elevations in intracellular calcium in rat bone marrow cell cultures via MC2-R signalingRegulation of bone remodeling by vasopressin explains the bone loss in hyponatremia.Age-Related Loss in Bone Mineral Density of Rats Fed Lifelong on a Fish Oil-Based Diet Is Avoided by Coenzyme Q10 Addition.There are many potential medical therapies for atraumatic osteonecrosis.Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease.High-density lipoprotein (HDL) metabolism and bone mass.NET amyloidogenic backbone in human activated neutrophils.Adrenocorticotropic hormone and 1,25-dihydroxyvitamin D3 enhance human osteogenesis in vitro by synergistically accelerating the expression of bone-specific genes.Do Neuroendocrine Peptides and Their Receptors Qualify as Novel Therapeutic Targets in Osteoarthritis?Neuronal Control of Bone Remodeling.Radon balneotherapy and physical activity for osteoporosis prevention: a randomized, placebo-controlled intervention study.Actions of pituitary hormones beyond traditional targets.
P2860
Q28487124-58EC95CA-CC29-4453-83F4-1B79D775EC7BQ34356431-8EAC9ECC-B608-4A6D-B618-69260A03A83CQ34386283-2EA03C8E-B1E6-4271-8FE7-FFBF1D8A5A3AQ35025528-CAD65C1E-3EF2-4D1B-8528-FFE53C8A7784Q36134548-B11FD651-AC4F-4BA1-B3D6-5252B246BB2CQ36217229-FE1DE983-7ACB-4F99-BA5F-2C2BD60C1AF9Q36290316-CC64D243-197B-4B66-8629-214CAA6D098AQ36361763-4DB19635-4145-4A50-8D63-46E5E8D0DAA1Q36395186-C3278DA8-657D-4639-86F1-534619710BC1Q36459341-0D82CE29-1861-43A7-AABF-AA3F2E7B3C2DQ36807768-FACE002B-3321-4002-9E82-E36B559F2569Q37319607-BBBCA6DA-AD19-4DEA-8980-983D91AD7207Q37673302-77DC66B0-E5D7-4D9D-97E8-76D3644E26A8Q38049949-FACDCB04-A3FB-4D87-9B7F-A4873BE07103Q38603477-B4A8505D-47FD-48E2-817C-10508594853EQ38743436-52EBBDF9-750A-4A55-946E-26E202ADB767Q41227549-ACAE4367-6152-4C91-9B81-82B7B8183157Q45064023-0280AAC3-CBE6-4DA5-A489-34BA4530AF52Q47709852-B8902E3E-4D78-4C0E-B71B-7F1E2E2BA0FEQ47981326-F7CF93D0-DB67-402C-8020-57F8EFC81E9FQ48063993-EABBC649-95E8-4200-9BBB-A6A2C8D20C48Q52647974-A23B0E57-6FBF-4C9F-8916-3C0D3D19C869
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
ACTH is a novel regulator of bone mass.
@ast
ACTH is a novel regulator of bone mass.
@en
ACTH is a novel regulator of bone mass.
@nl
type
label
ACTH is a novel regulator of bone mass.
@ast
ACTH is a novel regulator of bone mass.
@en
ACTH is a novel regulator of bone mass.
@nl
prefLabel
ACTH is a novel regulator of bone mass.
@ast
ACTH is a novel regulator of bone mass.
@en
ACTH is a novel regulator of bone mass.
@nl
P2093
P1476
ACTH is a novel regulator of bone mass.
@en
P2093
Carlos M Isales
Harry C Blair
Mone Zaidi
P304
P356
10.1111/J.1749-6632.2009.05231.X
P407
P577
2010-03-01T00:00:00Z